Anumana named in Fierce Medtech's Fierce 15 for 2022
Leveraging cutting-edge AI, industry-leading translational science and deep electrophysiological data to transform cardiac care
Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology.
Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate, at times resulting in life-threatening events. Anumana’s AI solutions enable earlier diagnosis of these otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes.
Today, the power of AI is just beginning to be leveraged in EP clinical decision support and can provide immense value during EP procedures. Anumana’s algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes.
Anumana has one of the world’s largest electrophysiological data and longitudinal patient history and outcomes in the world. This harmonized, cleaned, and validated dataset was developed from multi-year data partnerships with several health systems from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transforms unstructured data (i.e. clinical notes, echocardiogram reports) and semi-structured (i.e. lab tests, medications, appointments, etc) into labeled data format at scale. This extensive data platform is the basis upon which Anumana’s research is conducted.
Anumana develops state-of-the-art ECG-AI and EGM-AI algorithms which are rooted in science and backed by a growing body of data. The growing pipeline of ECG-AI algorithms have been validated by over 75 peer-reviewed publications, including The Lancet and Nature.
Anumana builds and commercializes clinician-facing software and solutions to democratize insights from its cardiology-AI. Anumana’s software solutions seamlessly integrate with EMRs and other point-of-care technology used within the clinician’s workflow.
Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.
Granted FDA Breakthrough Device Designation
Anumana also has a rich pipeline of AI / ML driven products for use in the interventional electrophysiology (EP) setting.
FDA Clearance Not Required
See Anumana’s work in the news
AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care
Mar. 20th, 2023
FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help diagnose cases of cardiac amyloidosis, where misfolded proteins build up around the tissue.
Dec. 16th, 2022
FIERCE Biotech: Mayo Clinic’s artificial intelligence spinout Anumana is taking a deeper dive into analyzing the pulsing electrical signals of the heart with a new acquisition aimed at developing software used during cardiac procedures.
Nov. 8th, 2022
Med City News: Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.
Jul. 14th, 2022
Learn more about Anumana’s algorithms validated in 75+ peer reviewed publications.
Aug. 8th, 2022
Nov. 13th, 2022
Nov. 14th, 2022
Nov. 1st, 2022
In just the past three years, the team has published more than two dozen studies on AI in cardiology, and it is now field-testing an algorithm to detect a weak heart pump in dozens of primary care clinics.
Dec. 18th, 2019
Featuring key corporate highlights and an overview of Anumana's technology
@2023 anumana, Inc. All rights reserved.